Investor Relations –

Shareholder
Services

FAQs –

Investors FAQs.

The Company address is 701 Tillery St #12 #1010 Austin, TX 78702. The main office number is 512-200-2982.

Faeth was incoroporated as Sensei Biotherapeutics, Inc in Delaware in 2017.

Shares of Faeth are traded on the NASDAQ Capital Market under the ticker symbol FTH. The CUSIP number is 81728A1207

Faeth’s fiscal year ends on December 31st.

Faeth’s transfer agent is Equiniti Trust Company, LLC.

Shares can be purchased through a stockbroker of your choice. Faeth does not currently have a direct stock purchase plan.

Faeth does not currently pay a dividend or offer a dividend reinvestment program.

Faeth’s independent registered public accountant is Deloitte & Touche LLP, 500 East Pratt Street, Suite 500, Baltimore, MD 21202.

Corporate news can be found in the News & Events section of Faeth’s Investors website. Quarterly and annual reports, as well as other SEC filings, can be found in the SEC filings section of the Investors website or directly from the SEC att www.sec.gov.

Please contact ir@faeththerapeutics.com with any additional inquiries.

You may unsubscribe at any time. Faeth Therapeutics does not sell or share your email address with third parties. By subscribing, you agree to receive electronic communications from Faeth Therapeutics, Inc. If you would like to opt out of email alerts, you can unsubscribe here.

Email Alerts –

Stay informed.

Stay informed about press releases, SEC filings, upcoming events, and financial results from Faeth Therapeutics. To opt-in for investor email alerts, please select at least one alert option and enter your email address in the field below. After submitting your request, an activation email will be sent to the address provided. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

 

Contact Us –

Contact investor relations.

For investor inquiries only, contact us directly or use the form.

ir@faeththerapeutics.com
 

The drug product candidates described on this website are investigational agents that have not been approved by the Food and Drug Administration or any other regulatory authority. Their safety and efficacy have not been established.